Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Volanesorsen Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Waylivra Receives Innovative Drug Category Pricing for FCS in Brazil
    Waylivra Receives Innovative Drug Category Pricing for FCS in Brazil

    04 Jan 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/waylivra-receives-innovative-drug-category-pricing-to-treat-familial-chylomicronemia-syndrome-in-brazil-301453143.html

    PRNEWSWIRE
    04 Jan 2022
    Share Share
    PTC Therapeutics Announces Waylivra™ Approval in Brazil
    PTC Therapeutics Announces Waylivra™ Approval in Brazil

    23 Aug 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-waylivra-approval-in-brazil-as-first-treatment-for-familial-chylomicronemia-syndrome-301360828.html

    PRNEWSWIRE
    23 Aug 2021
    Share Share
    WAYLIVRA?, the First and Only Therapy for Familial Chylomicronaemia
    WAYLIVRA?, the First and Only Therapy for Familial Chylomicronaemia

    09 Nov 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201109005111/en

    BUSINESSWIRE
    09 Nov 2020
    Share Share
    NICE relents and okays Akcea’s rare disease drug Waylivra for NHS use
    NICE relents and okays Akcea’s rare disease drug Waylivra for NHS use

    21 Sep 2020

    // Phil Taylor PHARMA PHORUM

    https://pharmaphorum.com/news/nice-relents-and-okays-akceas-rare-disease-drug-waylivra-for-nhs-use/

    Phil Taylor PHARMA PHORUM
    21 Sep 2020
    Share Share
    Akcea's WAYLIVRA® (volanesorsen) to Be Available on the NHS in England
    Akcea's WAYLIVRA® (volanesorsen) to Be Available on the NHS in England

    18 Sep 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200918005029/en/WAYLIVRA%E2%96%BC%C2%AE-volanesorsen-the-First-and-Only-Therapy-for-FCS-an-Ultra-Rare-and-Life-Threatening-Condition-to-Be-Available-on-the-NHS-in-England

    BUSINESSWIRE
    18 Sep 2020
    Share Share
    NICE u-turn sees Akcea's Waylivra win NHS funding
    NICE u-turn sees Akcea's Waylivra win NHS funding

    18 Sep 2020

    // Selina McKee PHARMATIMES

    http://www.pharmatimes.com/news/nice_u-turn_sees_akceas_waylivra_win_nhs_funding_1350842

    Selina McKee PHARMATIMES
    18 Sep 2020
    Share Share